Business Context and Reporting Period
Company: TopSpin Medical, Inc. (Note: Input metadata referenced "My Size, Inc.", but the filing text identifies the registrant as TopSpin Medical, Inc.)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: The Company was originally engaged in the R&D of MRI technology using miniaturized sensors. However, due to severe financial difficulties, the Company suspended all operational activities in October 2008. As of December 31, 2010, the Company had no revenue, no R&D activities, and only one full-time employee (the CEO). The Company filed for Chapter 11 bankruptcy relief in July 2010 to restructure its capital and debt.
Key Financial Metrics
| Metric | 2010 (NIS) | 2010 (USD Approx.) | 2009 (NIS) | 2009 (USD Approx.) |
|---|---|---|---|---|
| Revenue | 0 | $0 | 0 | $0 |
| Net Loss | (2,315,000) | ($620,145) | (1,676,000) | ($426,181) |
| Cash Flow from Operations | (2,570,000) | ($688,454) | (3,799,000) | ($1,015,000) |
| Cash and Equivalents (Year End) | 33,000 | $9,298 | 1,002,000 | $282,000 |
| Total Assets | 82,000 | $23,105 | 1,312,000 | $368,000 |
| Total Liabilities | 1,975,000 | $529,065 | 2,488,000 | $685,000 |
| Accumulated Deficit | (184,432,000) | ($51,967,315) | (182,117,000) | ($50,000,000) |
Note: USD conversions based on exchange rates provided in the filing (approx. NIS 3.549 to $1.00 for year-end balances).
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 40% from NIS 1.676 million in 2009 to NIS 2.315 million in 2010. This increase is primarily attributed to reorganization costs associated with Chapter 11 bankruptcy proceedings.
- General & Administrative Expenses: Increased by approximately 30% to NIS 2.512 million in 2010 from NIS 1.930 million in 2009, driven by legal and professional fees related to the bankruptcy filing.
- Financial Income: Decreased by 22% to NIS 197,000 in 2010 from NIS 254,000 in 2009, due to interest expenses on related party loans and foreign currency translation adjustments.
- Liquidity Deterioration: Cash and cash equivalents dropped significantly from NIS 1.002 million in 2009 to NIS 33,000 in 2010. Total assets declined from NIS 1.312 million to NIS 82,000 as the Company sold equipment and vacated office space.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The independent auditors have issued a "going concern" opinion, stating there is substantial doubt about the Company's ability to continue operations. The Company has no revenue and insufficient cash resources for the next twelve months.
- Chapter 11 Bankruptcy: The Company filed for Chapter 11 relief in July 2010. A reorganization plan was approved by shareholders in December 2010 and by the Bankruptcy Court on December 21, 2010. The plan included a 500:1 reverse stock split and the conversion of debt owed to Medgenesis Partners Ltd. into equity.
- Debt Restructuring: The Company secured loans from Medgenesis Partners Ltd. totaling approximately $428,000 (outstanding as of Dec 31, 2010) to fund legal fees and bankruptcy proceedings. This debt was subsequently classified as "receipts on account of shares" following the plan approval.
- Listing Status: The Tel Aviv Stock Exchange (TASE) notified the Company in February 2010 that it failed to meet minimum equity requirements. The Company was granted an extension until June 2012 to comply, or face delisting.
- Intellectual Property: In January 2010, management decided to discontinue the maintenance and development of its intellectual property, including a U.S. patent expiring in September 2011, due to the inability to complete product development.
Investor Verification Checklist
- Bankruptcy Plan Execution: Verify the final status of the Chapter 11 reorganization plan approved in December 2010, specifically the issuance of shares to Medgenesis and the 500:1 reverse stock split.
- Listing Compliance: Confirm whether the Company has met the TASE minimum equity requirements by the June 2012 deadline to avoid delisting.
- Cash Runway: Assess the Company's current cash position (approx. $9,300 as of Dec 2010) and any subsequent capital raises required to maintain operations or pursue new business ventures.
- Related Party Transactions: Review the terms of the debt-to-equity conversion with Medgenesis Partners Ltd. and the resulting ownership structure (Medgenesis expected to hold ~87% post-restructuring).
- Future Operations: Determine if the Company has successfully pivoted to new business activities in the life sciences sector as contemplated by management, given the suspension of MRI R&D.